CDK6 and astrocytoma (excluding glioblastoma): Specifically, in over 30% of patients with lower grade astrocytoma, new deletion of PTEN, CDKN2A, CDKN2B, or amplification of CDK6 and gain of KRAS were detected (Fig. 4a), which is consistent with previous reports10.